Health Management Program: Factors Influencing Completion of Therapy with High-Dose Interferon Alfa-2b for High-Risk Melanoma

N. Levesque; K. Mitchinson; D. Lawrie; L. Fedorak; D. MacDonald; C. Normand; J.F. Pouliot

doi:10.3747/co.2008.200

You are currently on the new version of our website. Access the old version .

Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..

Article

1 January 2008

Health Management Program: Factors Influencing Completion of Therapy with High-Dose Interferon Alfa-2b for High-Risk Melanoma

and

Hamilton Regional Cancer Centre, Hamilton, ON, Canada

Royal Victoria Hospital, Barrie, ON, Canada

Sunnybrook Regional Cancer Centre, Toronto, ON, Canada

⁴

Cross Cancer Institute, Edmonton, AB, Canada

Curr. Oncol.2008, 15(1), 36-41;https://doi.org/10.3747/co.2008.200

Version Notes

Order Reprints

Abstract

The goal of the 1-year observational, multicentre, open-label study reported here was to identify factors influencing adherence to high-dose interferon alfa-2b adjuvant therapy in patients at high risk of recurrence following surgical excision of malignant melanoma. The study was carried out in 23 tertiary-care centres across Canada.

Keywords:

melanoma; interferon alfa-2b; clinical trial; adherence

Article Metrics

Citations

Article Access Statistics

Journal Statistics

Multiple requests from the same IP address are counted as one view.

Cardiac Management during Adjuvant Trastuzumab Therapy: Recommendations of the Canadian Trastuzumab Working Group

Chinese Medicine and Biomodulation in Cancer Patients—Part One